Pfizer gets FDA approval for tick-borne encephalitis vaccine TICOVAC
Pfizer has secured approval for its TICOVAC vaccine from the US Food and Drug Administration (FDA) for active immunization against tick-borne encephalitis (TBE) in individuals aged one year and older.
TICOVAC is the only approved vaccine in the US for adults and children against the TBE virus when visiting or residing in TBE endemic areas.
Tick-borne encephalitis is a viral infection of the brain and spine. It can be transmitted to humans via the bite of an infected tick. Although the viral infection is not endemic in the US so far, it has been identified in 35 plus countries in Europe and Asia.
Nanette Cocero — Global President, Vaccines, Pfizer said: “We are proud to deliver the first vaccine to help protect people in the U.S. against TBE, if they are traveling to any risk areas.
“This vaccine has helped to protect millions of people in TBE endemic regions since its first approval outside the U.S. 45 years ago. This authorization helps to ensure that people from the U.S. are also able to receive this vaccination if needed, reflecting our commitment to provide health for all.”